8-K: Cardinal Health Q4 FY25 Earnings & FY26 Guidance Raise

Cardinal Health reported strong fourth-quarter and full-year fiscal 2025 results, raising its fiscal year 2026 non-GAAP EPS guidance and announcing the acquisition of Solaris Health.

Summary

• Fourth quarter fiscal year 2025 revenue was $60.2 billion, relatively flat year-over-year, but increased 21% excluding the impact of a previously communicated customer contract expiration.
• Fourth quarter non-GAAP operating earnings increased 19% to $719 million, driven by segment profit increases across Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other segments.
• Fourth quarter non-GAAP diluted EPS increased 13% to $2.08.
• Fiscal year 2025 revenues were $222.6 billion, a 2% decrease from fiscal year 2024, but increased 18% excluding the impact of a customer contract expiration.
• Fiscal year 2025 non-GAAP operating earnings increased 15% to $2.8 billion.
• Fiscal year 2025 non-GAAP diluted EPS increased 9% to $8.24.
• Fiscal year 2025 adjusted free cash flow was $2.5 billion.
• The company raised its fiscal year 2026 non-GAAP diluted EPS guidance to $9.30 to $9.50, an increase of $0.20 from the preliminary outlook of $9.10 to $9.30.
• Cardinal Health announced the definitive agreement to acquire Solaris Health, the country's leading urology MSO, for approximately $1.9 billion in cash, which will join The Specialty Alliance's Urology Alliance.

Sentiment

Score: 8

Explanation: The filing presents strong financial results for Q4 and FY25, particularly on a non-GAAP basis, and provides an optimistic outlook for FY26 with raised EPS guidance. The strategic acquisition of Solaris Health further strengthens the company's position in a key growth area. While there are noted risks and increased interest expenses, the overall tone and financial performance indicate a positive trajectory and strategic execution.

Positives

• Strong fourth quarter non-GAAP operating earnings growth of 19% and non-GAAP diluted EPS growth of 13%.
• All five operating segments achieved double-digit profit growth in the fourth quarter of fiscal year 2025.
• Raised fiscal year 2026 non-GAAP diluted EPS guidance by $0.20, indicating increased confidence in future performance.
• Strategic acquisition of Solaris Health expands the multi-specialty MSO platform, adding over 750 providers and accelerating growth strategy.
• Increased contributions expected from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in Other.
• Lower share count due to in-year share repurchases contributed to EPS growth.
• Achieved $2.5 billion in adjusted free cash flow for fiscal year 2025.

Negatives

• Fourth quarter revenue was relatively flat year-over-year, impacted by a customer contract expiration.
• Fiscal year 2025 total revenue decreased by 2% compared to fiscal year 2024.
• Increased interest and other expense due to financing costs related to recent acquisitions.
• Higher non-GAAP effective tax rate impacted diluted EPS.

Risks

• Failure to achieve strategic objectives, including the continued execution of the GMPD Improvement Plan initiatives.
• Impact of tariffs on sourced or manufactured products, an uncertain global economic and trade environment, or ongoing inflationary pressures.
• Uncertainty with respect to certain government initiatives, including the Executive Order regarding Most Favored Nation pricing for branded prescription pharmaceuticals and the One Big Beautiful Bill Act.
• Competitive pressures in various lines of business, including the risk that customers may reduce purchases or terminate/not renew contracts.
• Risks associated with litigation matters, including a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Events outside of control, such as weather or geopolitical events, impacting demand or causing supply shortages.
• Performance of the generics program, including the ability to offset generic deflation and maintain financial and strategic benefits.
• Risks associated with recently completed and pending acquisitions, including risks arising from entry into new lines of businesses.
• Risk that required regulatory approval or physician consents for the Solaris Health acquisition may not be received, or the transaction may otherwise fail to complete.
• Risk of failing to realize the anticipated strategic and financial benefits of the Solaris Health acquisition, whether due to external factors or unforeseen challenges.

Future Outlook

Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS guidance to $9.30 to $9.50, reflecting a $0.20 increase from previous preliminary outlook. This increase is attributed to a benefit from classifying shares held by physicians and management of The Specialty Alliance as a liability, and increased contributions from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in Other. The company expects strong revenue and segment profit growth across its Pharmaceutical and Specialty Solutions and Other segments, with more modest growth in Global Medical Products and Distribution. It also plans approximately $750 million in share repurchases and $2.75 billion to $3.25 billion in non-GAAP adjusted free cash flow for FY26.

Management Comments

• "Fiscal 2025 was a transformative year for Cardinal Health, and we closed the year with momentum, delivering strong fourth quarter results." Jason Hollar, CEO
• "The broad-based operational strength, with all five of our operating segments growing profit double-digits, reflects the disciplined execution of our strategy and our investments for growth." Jason Hollar, CEO
• "We enter Fiscal 2026 with confidence, evidenced by our increased financial outlook, as we continue to evolve towards reaching our full potential." Jason Hollar, CEO
• "Accelerating Specialty growth remains our top priority." Jason Hollar, CEO
• "As a physician, I know firsthand that integrated, coordinated care is critical to improving outcomes. By bringing Solaris Healths leading urology network into our platform, were helping specialty providers focus more of their time and energy where it matters most, on their patients." Dr. James Weber, CEO, The Specialty Alliance
• "Joining The Specialty Alliances Urology Alliance strengthens our ability to deliver exceptional, patient-centered care through a physician-led, national platform." Dr. Gary Kirsh, CEO, Solaris Health

Industry Context

The acquisition of Solaris Health aligns with a broader trend in healthcare towards consolidation and the expansion of multi-specialty management services organizations (MSOs). This move allows Cardinal Health to deepen its presence in the attractive urology specialty, leveraging its existing distribution and solutions capabilities to support physician practices. The focus on specialty growth and MSO platforms reflects a strategic shift to capture value beyond traditional pharmaceutical and medical product distribution, moving into direct patient care support and physician practice management, which is a growing area in the healthcare industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• The acquisition of Solaris Health, a leading urology MSO with over 750 providers across 14 states, positions Cardinal Health's Specialty Alliance as a significant player in the multi-specialty MSO space, reaching approximately 3,000 providers in 32 states upon transaction close. This scale is indicative of a strong market position within the MSO segment, particularly in urology, which is a growing and attractive specialty.

Management Changes

Legal Proceedings

• Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance, raised guidance, strategic acquisition, and continued share repurchases. Potential for increased debt but with a clear deleveraging plan.
• Employees: Growth in MSO platforms may lead to new opportunities.
• Customers (Physicians/Practices): Enhanced support and expanded network through the acquisition of Solaris Health and the broader Specialty Alliance.
• Patients: Improved access to specialized services and integrated care through the expanded urology network.

Next Steps

• Close the acquisition of Solaris Health by the end of calendar year 2025, subject to closing conditions, including required physician and regulatory approvals.
• Include the expected impact of the Solaris Health acquisition in fiscal year 2026 guidance after the acquisition is completed.
• Implement a focused approach to paying down debt over the next 18 to 24 months.
• Continue previously outlined share repurchases.
• Achieve targeted leverage range by the end of fiscal 2026.

Key Dates

Recommendation

Cardinal Health has demonstrated robust financial performance in Q4 and FY25, exceeding expectations with strong non-GAAP operating earnings and EPS growth. The significant increase in FY26 non-GAAP EPS guidance signals strong confidence in future profitability. The strategic acquisition of Solaris Health, a leading urology MSO, is a highly accretive move that expands the company's high-growth specialty segment and diversifies its revenue streams beyond traditional distribution. While increased debt for the acquisition is noted, the clear deleveraging plan and commitment to share repurchases mitigate this concern. The overall outlook is very positive, indicating strong operational momentum and strategic execution that should drive shareholder value.

Keywords

Cardinal Health, CAH, Pharmaceutical Distribution, Medical Products, Healthcare Services, Specialty Solutions, Urology MSO, Solaris Health, Earnings Report, Financial Guidance, Acquisition, SEC Filing